| B02BD06 |
Coagulation factor VIII, Factor von Willebrand |
WILATE 450 powder for solution for injection 450 IU x 1 |
Powder and solvent for solution for injection |
450 |
IU |
1 |
Octapharma (IP) Ltd., Обединено Кралство |
7200 |
IU |
962.53 |
6845.75977 |
427.86 |
100% |
|
Съгласно РУ |
№ 162/ 20.04.2011; НСР-3931/30.06.2014 |
02.08.2014 |
08.09.2012 |
Заличен |
723 |
| B02BD06 |
Coagulation factor VIII, Factor von Willebrand |
Wilate 500 |
Powder and solvent for solution for injection |
500 |
IU |
1 |
Octapharma (IP) SPRL, Белгия |
7200 |
IU |
471.14 |
6730.57143 |
471.14 |
100% |
|
Съгласно РУ |
НСР-1794/25.11.2013; НСР-5154/27.11.2014; КП-394/06.11.2015 и НСР-7055/03.09.2015; НСР-10295/15.09.2016; КП-142/08.11.2017 и НСР-13402/04.08.2017; АССГ № 481/19.01.2018 и НСР-10295/15.09.2016; НСР-17635/20.12.2018 |
02.02.2019 |
|
Активен |
3418 |
| B02BD06 |
Coagulation factor VIII, Factor von Willebrand |
WILATE 900 powder for solution for injection 900 IU x 1 |
Powder and solvent for solution for injection |
900 |
IU |
1 |
Octapharma (IP) Ltd., Обединено Кралство |
7200 |
IU |
856.92 |
6845.75977 |
855.72 |
100% |
|
Съгласно РУ |
№ 162/ 20.04.2011; КЦРР-2256/11.02.2013 и КП-4/05.02.2014; НСР-3931/30.06.2014 |
02.08.2014 |
08.09.2012 |
Заличен |
2556 |
| B02BD08 |
Eptacog alfa (activated) |
B02BD08 Eptacog alfa (activated) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| B02BD08 |
Eptacog alfa (activated) |
NovoSeven |
Powder and solvent for solution for injection |
2 mg (100KIU) |
|
1 vial + 1 vial |
Novo Nordisk A/S, Дания |
2500 |
KIU |
2590.99 |
64774.75 |
2590.99 |
100% |
|
Съгласно РУ |
№ 179/ 22.06.2011; КЦРР-1385/05.09.2012 г.; НСР-515/11.07.2013; НСР-3328/24.04.20124.; НСР-7854/15.01.2016.; НСР-15693/17.05.2018 |
02.06.2018 |
08.09.2012 |
Заличен |
2734 |
| B02BD08 |
Eptacog alfa (activated) |
NovoSeven |
Powder and solvent for solution for injection |
2 mg (100 KIU) |
|
1 vial + 1 syringe + 1 vial adapter |
Novo Nordisk A/S, Дания |
2500 |
KIU |
2369.39 |
59055 |
2362.2 |
100% |
|
Съгласно РУ |
НСР-11317/30.12.2016; НСР-18043/28.02.2019 предварително изпълнение; НСР-19909/03.10.2019 |
02.11.2019 |
|
Активен |
15557 |
| B02BD08 |
Eptacog alfa (activated) |
NovoSeven |
Powder and solvent for solution for injection |
5 mg (250 KIU) |
|
1 vial + 1 syringe + 1 vial adapter |
Novo Nordisk A/S, Дания |
2500 |
KIU |
5905.5 |
59055 |
5905.5 |
100% |
|
Съгласно РУ |
НСР-11317/30.12.2016 г.; НСР-18140/07.03.2019; НСР-19907/03.10.2019 |
02.11.2019 |
|
Активен |
15558 |
| B02BD08 |
Eptacog alfa (activated) |
NovoSeven 2.4 mg |
Powder and solvent for solution for injection |
120 |
KIU |
1 |
Novo Nordisk A/S, Дания |
2500 |
TIU |
3007 |
62645.83203 |
3007 |
100% |
|
Съгласно РУ |
КЦРР-982/16.07.2012 |
14.08.2012 |
08.09.2012 |
Заличен |
676 |
| B02BX04 |
Romiplostim |
B02BX04 Romiplostim |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| B02BX04 |
Romiplostim |
NPLATE |
Powder and solvent for solution for injection |
250 |
mcg |
1 |
Amgen Eurоpe B.V., Нидерландия |
30 |
mcg |
1203.31 |
144.45498 |
1203.31 |
100% |
|
Съгласно РУ |
КЦРР-961/16.07.2012 г.; НСР-238/24.06.2013; НСР-4595/15.09.2014; НСР-7364/05.11.2015; НСР-9630/23.06.2016; НСР-13885/25.09.2017; НСР-15817/08.06.2018; НСР-19402/02.08.2019 |
02.09.2019 |
08.09.2012 |
Активен |
3204 |
| B02BX04 |
Romiplostim |
NPLATE |
Powder for solution for injection |
250 |
mcg |
1 |
Amgen Eurоpe B.V., Нидерландия |
30 |
mcg |
1258.84 |
151.06081 |
1258.84 |
100% |
|
Съгласно РУ |
48/ 09.02.2010; КЦРР-2113/28.01.2013 г.; КЦРР-2474/27.02.2013 г.; НСР-2774/17.02.2014 |
16.03.2014 |
08.09.2012 |
Заличен |
1693 |
| B02BX04 |
Romiplostim |
NPLATE |
Powder for solution for injection |
500 |
mcg |
1 |
Amgen Eurоpe B.V., Нидерландия |
30 |
mcg |
2922.28 |
151.8817 |
2531.87 |
100% |
|
Съгласно РУ |
48/ 09.02.2010; КЦРР-1452/02.10.2012 г. |
09.11.2012 |
08.09.2012 |
Заличен |
775 |
| B02BX05 |
Eltrombopag |
B02BX05 Eltrombopag |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| B02BX05 |
Eltrombopag |
REVOLADE |
Film coated tablet |
25 |
mg |
28 |
Novartis Europharm Limited, Ирландия |
1 |
mg |
1888.8 |
2.69829 |
1888.8 |
100% |
|
Съгласно РУ |
№ 208/ 04.11.2011; НСР-857/09.08.2013; НСР-3591/23.05.2014; НСР-5575/05.02.2015.; НСР-8676/06.04.2016.; НСР-10996/24.11.2016; НСР-16372/02.08.2018; НСР-17882/07.02.2019 |
02.09.2019 |
08.09.2012 |
Активен |
3568 |
| B02BX05 |
Eltrombopag |
REVOLADE |
Film coated tablet |
50 |
mg |
28 |
Novartis Europharm Limited, Ирландия |
1 |
mg |
3765.62 |
2.68973 |
3765.62 |
100% |
|
Съгласно РУ |
№ 208/ 04.11.2011.; HCР-306/28.06.2013.; НСР-4739/02.10.2014.; НСР-6410/12.06.2015; НСР-8242/22.02.2016; НСР-10756/27.10.2016; НСР-16373/02.08.2018; НСР-17578/20.12.2018; НСР-18294/28.03.2019 |
02.05.2019 |
08.09.2012 |
Заличен |
3232 |
| B03AB04 |
Iron (III) - hydroxide polymaltose complex |
B03AB04 Iron (III) - hydroxide polymaltose complex |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| B03AB04 |
Iron (III) - hydroxide polymaltose complex |
MALTOFER |
Syrup |
10 mg/ml - 150 ml |
mg |
1 |
VIFOR France, SA, Франция |
1 |
mg |
5.9 |
0.00393 |
5.9 |
100% |
|
Съгласно РУ |
№ 20/15,07,2009
№40/27.08.2009; НСР-352/03.07.2013; НСР-4554/03.09.2014 |
02.10.2014 |
08.09.2012 |
Заличен |
2191 |
| B03AB04 |
Iron (III) - hydroxide polymaltose complex |
B03AB04 Iron (III) - hydroxide polymaltose complex |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| B03AB05 |
Iron (III) - hydroxide polymaltose complex |
MALTOFER DROPS |
|
50 mg/ml - 30 ml |
mg |
1 |
VIFOR France, SA, Франция |
1 |
mg |
4.92 |
0.00328 |
4.92 |
100% |
|
Съгласно РУ |
№ 20/15,07,2009
№40/27.08.2009; НСР-355/03.07.201; НСР-4132/23.07.2014; НСР-4552/03.09.2014 |
02.10.2014 |
08.09.2012 |
Заличен |
3045 |
| B03AB04 |
Iron (III) - hydroxide polymaltose complex |
B03AB04 Iron (III) - hydroxide polymaltose complex |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| B03AB05 |
Iron (III) - hydroxide polymaltose complex |
MALTOFER FOL |
Chewable tablet |
100 mg iron/0,35 mg folic acid |
mg |
30 |
VIFOR France, SA, Франция |
1 |
mg |
6.83 |
0.00228 |
6.83 |
100% |
|
Съгласно РУ |
№ 20/15,07,2009
№40/27.08.2009; НСР-362/03.07.2013; НСР-4553/03.09.2014 |
02.10.2014 |
08.09.2012 |
Заличен |
2190 |
| B03AB09 |
Iron proteinsuccinylate |
B03AB09 Iron proteinsuccinylate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| B03AB09 |
Iron proteinsuccinylate |
LEGOFER |
Oral solution |
150 |
ml |
1 |
Алкалоид ЕООД, България |
30 |
ml |
6.2 |
0.08266 |
6.2 |
100% |
|
Съгласно РУ |
№ 66/ 8.04.2010; НСР-7285/29.10.2015 |
02.12.2015 |
08.09.2012 |
Заличен |
104 |
| B03AC01 |
Ferric Carboxymaltose |
B03AC01 Ferric Carboxymaltose |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| B03AC01 |
Ferric carboxymaltose |
FERINJECT |
Solution for injection/infusion |
50 mg iron/ml - 10 ml |
mg |
1 |
VIFOR France, SA, Франция |
100 |
mg |
200.47 |
40.094 |
200.47 |
100% |
|
Съгласно РУ |
№ 201/ 19.10.2011; НСР-2397/21.01.2014; НСР-4942/22.10.2014.; НСР-6771/23.07.2015. |
16.05.2015 |
08.09.2012 |
Активен |
3282 |